Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,845.03
(
0.41%
)
US TECH 100
24,558.80
(
0.47%
)
Dow Jones
47,917.69
(
0.00%
)
Brent Oil
96.88
(
-2.98%
)
Bitcoin
72,277.52
(
2.12%
)
News Focus
News Focus
Post# of 257397
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122862
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: hptaxis post# 184132

Thursday, 01/22/2015 8:35:49 AM

Thursday, January 22, 2015 8:35:49 AM

Post# of 257397
BMRN sells 9.78M* shares @$93.25—a 3% discount to yesterday’s close:

http://finance.yahoo.com/news/biomarin-announces-pricing-public-offering-054022453.html

This offering will raise about $855M* in net proceeds, which is sufficient to pay for the RNA acquisition in the most expensive scenario where Proensa is approved by the FDA/EMA quickly (#msg-108456369).

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today